Active	Status	Sponsor type	Region	Phase	Filter
12 Active 0 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Arieli, Kimberly
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects	Recruiting	3	750	Europe, US	Placebo, GLSI-100	Greenwich LifeSciences, Inc.	Breast Cancer	12/26	12/26
NIR-OGT-201, NCT05348356 / 2022-001816-25: Nirogacestat in Ovarian Granulosa Cell Tumors	Active, not recruiting	2	53	Europe, Canada, US	Nirogacestat, PF-03084014	SpringWorks Therapeutics, Inc., SpringWorks Therapeutics, Inc.	Ovarian Granulosa-Stromal Tumor, Ovarian Granulosa Cell Tumor, Ovarian Cancer	07/26	12/27
Riaz, Fauzia
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects	Recruiting	3	750	Europe, US	Placebo, GLSI-100	Greenwich LifeSciences, Inc.	Breast Cancer	12/26	12/26
Le, Michelle
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects	Recruiting	3	750	Europe, US	Placebo, GLSI-100	Greenwich LifeSciences, Inc.	Breast Cancer	12/26	12/26